Didscussion  by unknown
in placing balloon-expandable stents. There is a learning
curve, both for sizing of grafts and implantation of devices,
for operators whose EVAR experience has been exclusively
with self-expanding stent grafts.
CONCLUSION
The Lifepath System demonstrates a low endoleak and
secondary intervention rate and high sac regression rate
compared with other devices. The unique balloon-expand-
able design offers the advantages of precise placement and
high radial force. The device appears to be highly resistant
to limb thrombosis and modular component separation.
Patients were protected from AAA rupture after successful
implantation of the device, and demonstrated significant
reduction in AAA diameter and volume. Fractures of the
wireforms of the main body of the device have been ob-
served. Careful follow-up of patients after EVAR is neces-
sary.
APPENDIX
The Lifepath AAA Graft System Investigators. Jens
Allenberg, MD, University of Heidelberg, Heidelberg,
Germany; Alain Branchereau, MD, Hospital de la Timone,
Marseille, France; Hugh G. Beebe, MD, Jobst Vascular
Center, Toledo, Ohio; David C. Brewster, MD, Massachu-
setts General Hospital, Boston, Mass; Jeffrey P. Carpenter,
MD, University of Pennsylvania, Philadelphia, Pa; John
Crouch, MD, St. Luke’s Medical Center, Milwaukee, Wis;
R. Clement Darling, MD, Albany Medical Center, Albany,
NY; Mark Fillinger, MD, Dartmouth Hitchcock Medical
Center, Lebanon, NH; Roy Fujitani, MD, University of
California, Irvine, Calif; Berndt Glucklich, MD, Kreiskran-
kenhaus Rendsburg, Rendsburg, Germany; Roy Green-
berg, MD, Cleveland Clinic Foundation, Cleveland, Ohio;
Svante Horsch, MD, Krankenhaus Porz am Rhein, Koln,
Germany; K. Craig Kent, MD, New York Hospital, New
York, NY; Chris Kwolek, MD, University of Kentucky,
Lexington, Ky; Werner Lang, MD, Klinikum der Friedrich-
Alexander-Universitat, Erlangen, Germany; Graham Long,
MD, William Beaumont Hospital, Detroit, Mich; Michel
Makaroun, MD, University of Pittsburgh, Pittsburgh, Pa;
John Martin, MD, Anne Arundel Vascular Institute, Prince
Frederick, Md; Richard McCann, MD, Duke University,
Durham, NC; William McKinsey, MD, University of Chi-
cago, Chicago, Ill; Andre Nevelsteen, MD, Dienst
Vaatheelkunde, Leuven, Belgium; Geoffrey White, MD,
Royal Prince Alfred Hospital, Camperdown, NSW, Austra-
lia; Rodney White, MD, Harbor UCLA Medical Center,
Torrance, Calif.
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DISCUSSION
Dr Richard M. Green (Rochester, NY). Dr. Carpenter, that
was nicely presented. Can you give us a sense—you’ve used a lot of
different devices—as to what the specific role of this graft will be,
what the advantages are, disadvantages are, relative to some of the
others. There are a lot of the same anatomic indications for the
currently approved devices.
Dr Jeffrey P. Carpenter. That’s an excellent question: Where
does this device fit in?
I think what distinguishes it from the other devices, of course,
is the fact that it’s a balloon-expandable device. It offers the ability
to make very fine adjustments during deployment. It deploys quite
accurately.
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The high radial force is another feature of it that is unique. It
will straighten an angulated aortic neck. I’ve had trouble getting
self-expanding devices to seal in the angulated situation; and, of
course, the remedial procedure for that problem is placement of a
balloon-expandable stent in the neck. Here you’re starting with a
high radial force situation from the outset.
I’m also very impressed with the sac regression data and the
effective prevention of AAA rupture.
Dr Robert B. Rutherford (Corpus Christi, Tex). Am I
correct that only 79 of the 227 were the first iteration?
Dr Carpenter. That’s correct.
Dr Rutherford. They must be bifurcation endografts only,
then. And what were the changes that were made in the redesigned
endografts that are leading to these improved results in terms of
wireform fractures? Originally it was said that they were going to
thicken the wireforms and do something else to them, like burnish
them; but it has not been made clear exactly what changes were
made that now have led to these improved results.
Dr Carpenter. That’s precisely it, Dr Rutherford. The wires
are made of the same material, just thickened.
Dr Jacob Buth (Eindhoven, The Netherlands). Thank you
for this nice presentation.
Can you elaborate a bit more on the differences between the
Lifepath and other devices, for instance, with regard to the avail-
able size range of this particular device. I believe the maximum
sizes are smaller than for the other device brands, which may be
due to a thicker fabric. Can you confirm that?
Dr Carpenter. The fabric is a full-thickness, surgical weight
polyester. In the trial the device was used to treat aneurysms
between 19-mm and 27-mm diameter neck. There is an aortic cuff
available up to 31 mm, which should be able to extend that range to
29 mm. And I know the Lifepath team is planning larger sizes. But for
the purposes of the trial, we treated 19-mm to 27-mm neck diameters.
Dr Buth. And thinking of the previous talk, are there any
specific oversizing recommendations? I thought it was a bit differ-
ent in Lifepath from other devices.
Dr Carpenter. That’s an excellent point. The sizing issues are
different owing to the balloon-expandable delivery. Diameter mea-
surements are performed intima to intima. Oversizing is less than
with other devices. The protocol specifies 10% to 15%. In practice,
most of us oversize about 10%.
Dr Buth. Were there breaks with the protocol in the two
ruptures?
Dr Carpenter. I do not believe that there were breaks that
were identified. We’ve been over those patients many times. At the
time of conversion, both were described to have extremely thin
aortas.
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